Skip to content
Catalyst

fucoxanthinWhat was measured

Measured, with no finding

601 endpoints

Show what was measuredHide what was measured
  • body fat reduction

    decreases, p = 0.001, n = 113

    (3.5 +/- 1.9 kg NAFLD group, p < 0.001; 3.6 +/- 0.7 kg NLF group, p < 0.05)

    PMID 19840063 · one of two readings recorded this

  • body fat reduction

    decreases, p = 0.05, n = 38

    (3.5 +/- 1.9 kg NAFLD group, p < 0.001; 3.6 +/- 0.7 kg NLF group, p < 0.05)

    PMID 19840063 · one of two readings recorded this

  • body weight reduction

    decreases, p = 0.05, n = 113

    Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight (5.5 +/- 1.4 kg NAFLD group and 4.9 +/- 1.2 kg NLF group, p < 0.05)

    PMID 19840063 · one of two readings recorded this

  • body weight reduction

    decreases, p = 0.05, n = 38

    Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight (5.5 +/- 1.4 kg NAFLD group and 4.9 +/- 1.2 kg NLF group, p < 0.05)

    PMID 19840063 · one of two readings recorded this

  • liver fat content, liver enzymes, serum triglycerides and C-reactive protein

    decreases

    and liver fat content, liver enzymes (NAFLD group only), serum triglycerides and C-reactive protein

    PMID 19840063 · one of two readings recorded this

  • resting energy expenditure

    increases, n = 41

    Fucoxanthin (> 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased REE in NAFLD subjects compared to placebo

    PMID 19840063 · one of two readings recorded this

  • resting energy expenditure

    increases, n = 41

    Fucoxanthin (> 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased REE in NAFLD subjects compared to placebo

    PMID 19840063 · one of two readings recorded this

  • waist circumference

    decreases

    waist circumference (NAFLD group only)

    PMID 19840063 · one of two readings recorded this

  • cell viability and apoptosis in MCF-7 and MDA-MB-231 breast cancer cell lines

    decreases

    In addition, our research group have shown that 10–20 µM Fx and Fxol have inhibitory effects on cell viability and apoptosis-inducing effects on two human breast cancer cell lines, MCF-7 and MDA-MB-231.

    PMID 26264004 · one of two readings recorded this

  • nuclear SOX9 expression in MDA-MB-231 cells

    decreases

    In MDA-MB-231, SOX9 was decreased at the nuclear level by Fx and Fxol.

    PMID 26264004 · one of two readings recorded this

  • action potential plateau phase duration

    decreases

    67.3 ± 0.70 ms in the fucoidan-fed, 59.31 ± 0.96 ms in the fucoxanthin-fed, and 39.84 ± 1.06 ms in mice fed with both fucoidan and fucoxanthin

    PMID 30669571 · one of two readings recorded this

  • action potential plateau phase duration

    decreases

    67.3 ± 0.70 ms in the fucoidan-fed, 59.31 ± 0.96 ms in the fucoxanthin-fed, and 39.84 ± 1.06 ms in mice fed with both fucoidan and fucoxanthin

    PMID 30669571 · one of two readings recorded this

  • action potential plateau phase duration

    decreases

    67.3 ± 0.70 ms in the fucoidan-fed, 59.31 ± 0.96 ms in the fucoxanthin-fed, and 39.84 ± 1.06 ms in mice fed with both fucoidan and fucoxanthin

    PMID 30669571 · one of two readings recorded this

  • action potential plateau phase duration

    increases

    The plateau phase was 29.28 ± 1.18 ms in the young control, 153.7 ± 6.47 ms in the aging control

    PMID 30669571 · one of two readings recorded this

  • cardiac fibrosis (Masson's trichrome)

    decreases

    In the treated groups, the cardiac fibrosis was significantly reduced in the ventricle areas of the FD, FX, and FD + FX groups

    PMID 30669571 · one of two readings recorded this

  • cardiac fibrosis (Masson's trichrome)

    increases

    the cardiac tissue from the SC group indicated a high proportion of fibrosis over almost the entire area

    PMID 30669571 · one of two readings recorded this

  • CREB protein expression

    increases

    The CREB protein was highest in the YC group when compared to the rest of the groups

    PMID 30669571 · one of two readings recorded this

  • Development_PIP3 signaling in cardiac myocytes pathway enrichment (GSE76374 fucoidan vs control)

    modulates, p = 5.436e-13

    was the most significant pathway between the fucoidan-treated group and the control group with p value = 5.436 × 10−13 and FDR = 2.549 × 10−12

    PMID 30669571 · one of two readings recorded this

  • exhaustive swimming time

    decreases, p = 0.05

    There were also significant differences between the fucoidan and fucoxanthin groups and the YC group (p < 0.05)

    PMID 30669571 · one of two readings recorded this

  • exhaustive swimming time

    decreases

    The aging control group had a significantly lower swimming duration (lower muscle endurance) compared to the YC group

    PMID 30669571 · one of two readings recorded this

  • forelimb grip strength

    increases

    There were significant improvements after treatment with fucoidan and fucoxanthin

    PMID 30669571 · one of two readings recorded this

  • forelimb grip strength

    decreases

    The SC group did significantly worse in the forelimb gripping test than the YC group

    PMID 30669571 · one of two readings recorded this

  • GRB2 protein expression

    decreases

    GRB2 protein expression level was high in the YC, SC, FX, and FD groups but not in the FD + FX group

    PMID 30669571 · one of two readings recorded this

  • GSK3β protein expression

    increases

    Fucoidan alone kept the expression level of this protein unchanged, whereas fucoidan in combination with HSFUCO (FD + FX) and HSFUCO (FX) alone showed increases in the level of GSK3β protein

    PMID 30669571 · one of two readings recorded this

  • GSK3β protein expression

    decreases

    The GSK3β protein expression level was higher in the young control subjects than in the aging control group

    PMID 30669571 · one of two readings recorded this

  • IRS1 protein expression

    increases

    The IRS1 protein level was also high in YC, FX, FD, and FX + FD but not in the SC group

    PMID 30669571 · one of two readings recorded this

  • most significant metabolic pathways in aging

    modulates

    Steroid hormone biosynthesis, the citrate cycle (TCA cycle), and the glycolysis cycle were the three most significant metabolic pathways involved in the aging process

    PMID 30669571 · one of two readings recorded this

  • QT interval on three-lead ECG (PowerLab/4SP) and ventricular action potential plateau duration by patch-clamp in two-year-old C57BL/6 mice given HSFUCO 500 mg/kg orally for 28 days, versus aging control; also forelimb grip strength, forced-swim exhaustion time, RBC reactive oxygen species

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    The experimental groups’ QT interval was reduced when treated with LMF and HSFUCO either alone or in combination (FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec).

    PMID 30669571 · one of two readings recorded this

  • QT interval

    decreases

    FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec

    PMID 30669571 · one of two readings recorded this

  • QT interval

    decreases

    FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec

    PMID 30669571 · one of two readings recorded this

  • QT interval

    decreases

    FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec

    PMID 30669571 · one of two readings recorded this

  • QT interval

    increases

    Prolonged QT interval was determined in the aging mice control group (SC) (25.6 ± 1.35 msec) relative to the young control group (13.62 ± 0.68 msec)

    PMID 30669571 · one of two readings recorded this

  • red blood cell ROS activity (relative to SC = 100%)

    decreases

    the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively

    PMID 30669571 · one of two readings recorded this

  • red blood cell ROS activity (relative to SC = 100%)

    decreases

    the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively

    PMID 30669571 · one of two readings recorded this

  • red blood cell ROS activity (relative to SC = 100%)

    decreases

    the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively

    PMID 30669571 · one of two readings recorded this

  • red blood cell ROS activity (relative to SC = 100%)

    increases

    the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively

    PMID 30669571 · one of two readings recorded this

  • red blood cell ROS activity (relative to SC = 100%)

    decreases

    the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively

    PMID 30669571 · one of two readings recorded this

  • SOS1 protein expression

    increases

    Under treatment by HSFUCO, the expression level of SOS1 was increased compared to that of the aging group

    PMID 30669571 · one of two readings recorded this

  • SOS1 protein expression

    no effect

    the combined effect of fucoidan and HSFUCO showed a comparable level of SOS1 protein expression to that of the aging group

    PMID 30669571 · one of two readings recorded this

  • urinary metabolite profile (PLS-DA, 57 metabolites)

    modulates

    The young control and aging control subjects could be distinguished from the aging subjects treated with fucoidan (FD); however, the FD mice did not come close to the YC group

    PMID 30669571 · one of two readings recorded this

  • fasting blood glucose

    increases

    PTE300-supplemented mice, which had fasting blood glucose levels significantly higher than control and PTE100-supplemented mice

    PMID 30959933 · one of two readings recorded this

  • HOMA-IR

    decreases, p = 0.068

    There was a tendency for decreased HOMA-IR index (p = 0.068; Mann–Whitney U test)

    PMID 30959933 · one of two readings recorded this

  • body weight gain, EchoMRI total body fat mass, WAT depot weights, inguinal adipocyte size and WAT gene expression in HFD-fed C57BL/6J mice given ethanolic Phaeodactylum tricornutum extract (PTE) 100 or 300 mg/kg/day

    decreases

    Not recorded as a finding: the intervention held more than the compound

    The PTE300 group also revealed less total body fat mass than controls in body composition analyses performed after 5, 14, and 22 days on the HFD.

    PMID 30959933 · one of two readings recorded this

  • body weight gain, total body fat mass by EchoMRI, epididymal and inguinal WAT mass in HFD-fed C57BL/6J mice

    decreases, PTE300 mice gained less body weight than controls, statistically significant for PTE300

    Not recorded as a finding: the intervention held more than the compound

    The PTE-treated mice gained less body weight than controls upon HFD feeding, an effect that reached statistical significance for PTE300.

    PMID 30959933 · one of two readings recorded this

  • body weight gain

    decreases

    control, PTE100, and PTE300 mice had gained 7.0 ± 0.5, 6.0 ± 1.0, and 4.5 ± 0.5 g

    PMID 30959933 · one of two readings recorded this

  • body weight lost upon 6 h fast

    increases

    Body weight lost upon a 6 h fast, used as an indicator of energy expenditure, was maximal in the PTE300 group

    PMID 30959933 · one of two readings recorded this

  • Cd36 mRNA expression in 3T3-L1 adipocytes

    increases

    Cd36 mRNA levels were induced following exposure to PTE, but not fucoxanthin

    PMID 30959933 · one of two readings recorded this

  • Cd36 mRNA expression in BAT

    increases, p = 0.046

    increased gene expression in BAT of Cd36 (p = 0.046; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • Cd36 mRNA expression

    decreases, p = 0.078

    there were trends to down-regulation for the lipogenesis-related gene Srebf1 and the fatty acid uptake-related gene Cd36 as well (p = 0.099 and p = 0.078, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • Cpt1 mRNA expression

    increases, p = 0.085

    Cpt1 was 4 times and Ucp1 at least 11 times upregulated in inguinal WAT of PTE-supplemented mice, indicating an increased capacity for fatty acid oxidation and thermogenesis (p = 0.085 and p = 0.022, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • Cpt1a mRNA expression in 3T3-L1 adipocytes

    increases

    Cpt1a mRNA levels were strongly, relative to levels in control cells, similarly induced by both PTE and fucoxanthin exposure

    PMID 30959933 · one of two readings recorded this

  • crown-like structures in inguinal WAT

    increases

    an even more consistent occurrence of CLS was found in the PTE300-supplemented group, for which CLSs were detected in all five animals examined

    PMID 30959933 · one of two readings recorded this

  • energy intake

    no effect

    Differences in body weight gain were not because of the differences in energy intake, which was similar in the three experimental groups throughout the entire duration of the HFD challenge

    PMID 30959933 · one of two readings recorded this

  • epididymal depot weight as percentage of body weight (adiposity index)

    decreases

    The weight of the epididymal depot expressed as percentage of body weight, which is commonly used as an adiposity index in mice, was significantly lower in the PTE300 group compared to the control group

    PMID 30959933 · one of two readings recorded this

  • epididymal WAT mass

    decreases

    the mass of the epididymal and inguinal WAT depots was significantly lower (by 24% and 17%, respectively) in the PTE300 group compared with the control group

    PMID 30959933 · one of two readings recorded this

  • Fasn mRNA expression in 3T3-L1 adipocytes

    decreases

    Fasn mRNA levels were decreased following exposure to fucoxanthin, but not PTE

    PMID 30959933 · one of two readings recorded this

  • Fasn mRNA expression in BAT

    decreases, p = 0.049

    mRNA levels of the lipogenic genes Fasn and Srebf1 were also down-regulated in BAT of PTE-supplemented mice (p = 0.049 and p = 0.074, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • fed blood glucose

    no effect

    Fed blood glucose levels at the end of the experiment did not significantly differ between groups (control, 180 ± 8.1; PTE100, 186 ± 9.8; PTE300, 191 ± 10.7 mg/dL)

    PMID 30959933 · one of two readings recorded this

  • final body weight

    decreases

    final body weights were 35.1 ± 0.6, 33.5 ± 1.4, and 33 ± 0.7 g

    PMID 30959933 · one of two readings recorded this

  • inguinal WAT adipocyte size distribution

    decreases, p = 0.001

    The Kolmogorov–Smirnov test indicated that the difference in distributions of cell size between control and PTE-supplemented mice was statistically significant (p < 0.001 for both PTE doses)

    PMID 30959933 · one of two readings recorded this

  • inguinal WAT mass

    decreases

    the mass of the epididymal and inguinal WAT depots was significantly lower (by 24% and 17%, respectively) in the PTE300 group compared with the control group

    PMID 30959933 · one of two readings recorded this

  • initial body weight

    no effect

    The average initial body weight was 27.7 ± 0.5 g and did not differ significantly among the three experimental groups

    PMID 30959933 · one of two readings recorded this

  • Lipe mRNA expression in BAT

    decreases, p = 0.029

    downregulated expression in BAT of the lipolytic genes Lipe and Pnpla2 (p = 0.029 and p = 0.057, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • Lipe mRNA expression

    decreases, p = 0.039

    mRNA levels of lipolysis-related genes Lipe, encoding hormone sensitive lipase, and Plin1, encoding perilipin 1, were significantly down-regulated (p = 0.039 and p = 0.033, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • lipid metabolism gene expression (same genes as epididymal)

    no effect

    In subcutaneous (inguinal) WAT, expression of these same genes was unaffected by PTE supplementation

    PMID 30959933 · one of two readings recorded this

  • liver histology (hepatosteatosis)

    no effect

    Histological analysis of the liver was largely normal and did not reveal obvious hepatosteatosis in any of the experimental groups

    PMID 30959933 · one of two readings recorded this

  • Lpl mRNA expression

    decreases

    mRNA levels in the epididymal fat depot of Lpl, coding for lipoprotein lipase that enables utilization of fatty acids from circulating triacylglycerols, were significantly down-regulated in the PTE300 mice relative to controls

    PMID 30959933 · one of two readings recorded this

  • Mest mRNA expression

    decreases

    mRNA expression levels of mesoderm-specific transcript homolog protein (Mest), used as a marker of WAT expansion, were markedly decreased in inguinal WAT of PTE-supplemented mice

    PMID 30959933 · one of two readings recorded this

  • Plin1 mRNA expression

    decreases, p = 0.033

    mRNA levels of lipolysis-related genes Lipe, encoding hormone sensitive lipase, and Plin1, encoding perilipin 1, were significantly down-regulated (p = 0.039 and p = 0.033, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • Pnpla2 mRNA expression in BAT

    decreases, p = 0.057

    downregulated expression in BAT of the lipolytic genes Lipe and Pnpla2 (p = 0.029 and p = 0.057, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • R-QUICKI

    increases, p = 0.1

    increased R-QUICKI index (p = 0.100; Mann–Whitney U test) in the PTE100-supplemented group

    PMID 30959933 · one of two readings recorded this

  • retroperitoneal WAT mass and BAT mass

    no effect

    There were no differences between groups in retroperitoneal WAT mass and BAT mass

    PMID 30959933 · one of two readings recorded this

  • Srebf1 mRNA expression in BAT

    decreases, p = 0.074

    mRNA levels of the lipogenic genes Fasn and Srebf1 were also down-regulated in BAT of PTE-supplemented mice (p = 0.049 and p = 0.074, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • Srebf1 mRNA expression

    decreases, p = 0.099

    there were trends to down-regulation for the lipogenesis-related gene Srebf1 and the fatty acid uptake-related gene Cd36 as well (p = 0.099 and p = 0.078, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • total body fat mass

    decreases

    The PTE300 group also revealed less total body fat mass than controls in body composition analyses performed after 5, 14, and 22 days on the HFD

    PMID 30959933 · one of two readings recorded this

  • total liver lipid content

    decreases

    Biochemical analysis showed a tendency for lower total liver lipid content in the PTE-supplemented mice

    PMID 30959933 · one of two readings recorded this

  • Ucp1 and Cpt1 mRNA expression in BAT

    no effect

    PTE supplementation had no effect on the expression of Ucp1 or Cpt1 at the mRNA level

    PMID 30959933 · one of two readings recorded this

  • UCP1 and MFN2 protein in BAT

    increases

    showing dose-dependent increased levels of both proteins in BAT of PTE-supplemented animals as compared to controls

    PMID 30959933 · one of two readings recorded this

  • Ucp1 mRNA detection in 3T3-L1 adipocytes

    no effect

    Ucp1 mRNA could not be detected in mature 3T3-L1 adipocytes irrespective of treatment

    PMID 30959933 · one of two readings recorded this

  • Ucp1 mRNA expression

    increases, p = 0.022

    Cpt1 was 4 times and Ucp1 at least 11 times upregulated in inguinal WAT of PTE-supplemented mice, indicating an increased capacity for fatty acid oxidation and thermogenesis (p = 0.085 and p = 0.022, respectively; Kruskal–Wallis test)

    PMID 30959933 · one of two readings recorded this

  • UCP1 protein in inguinal WAT

    increases

    UCP1 could not be detected in inguinal WAT in any control mice, but it was detected by immunoblotting in one-sixth PTE100 and two-fifths PTE300 mice analyzed (results not shown)

    PMID 30959933 · one of two readings recorded this

  • 3T3-L1 cell cytotoxicity of FX

    no effect

    We indicated that FX was not toxic to cells below 80 μM, and PE showed cytotoxicity at 1000 μg/mL (Figure S2)

    PMID 31137922 · one of two readings recorded this

  • 3T3-L1 cell cytotoxicity of PE

    decreases

    We indicated that FX was not toxic to cells below 80 μM, and PE showed cytotoxicity at 1000 μg/mL (Figure S2)

    PMID 31137922 · one of two readings recorded this

  • abdominal fat volume (micro CT)

    decreases

    For abdominal fat, the values in the PE-treated groups were 43.34~57.96% of that in the HFD

    PMID 31137922 · one of two readings recorded this

  • body weight AUC

    decreases

    Mice in the HFD plus PE treatment group showed a lower AUC level than the HFD group, while mice in the PE plus conjugated linoleic acid (CLA) group showed the lowest AUC level

    PMID 31137922 · one of two readings recorded this

  • body weight AUC

    increases, p = 0.001

    After 6 weeks, the area under the curve (AUC) of body weights was higher in the HFD group than in the normal diet (ND) group and other groups (p < 0.001)

    PMID 31137922 · one of two readings recorded this

  • body weight gain

    decreases

    all PE-treated groups showed weight loss in a dose-dependent manner compared to the HFD group, with greater effects than in the positive control (FX)

    PMID 31137922 · one of two readings recorded this

  • C/EBPα expression in adipose tissue

    decreases

    In addition, C/EBPα expression levels were lower in the PE-treated groups

    PMID 31137922 · one of two readings recorded this

  • C/EBPα protein level in 3T3-L1 cells

    no effect

    However, neither FX nor PE affected the level of C/EBPα

    PMID 31137922 · one of two readings recorded this

  • inguinal adipose tissue weight

    increases

    Inguinal adipose tissue weight was significantly higher in the HFD group than the ND group on both the right and left

    PMID 31137922 · one of two readings recorded this

  • inguinal adipose tissue weight

    decreases

    the PE-treated groups exhibited lower values than the HFD group in inguinal adipose tissue weight over 40% (p < 0.01 or p < 0.05)

    PMID 31137922 · one of two readings recorded this

  • initial body weight

    no effect

    Before treatment, the average initial body weight of the mice was 24.38 g, with no significant differences among the 7 groups

    PMID 31137922 · one of two readings recorded this

  • intracellular lipid accumulation (Oil Red O) in 3T3-L1 cells

    decreases

    FX at 40 μM inhibited lipid accumulation by 30% compared to the control during differentiation

    PMID 31137922 · one of two readings recorded this

  • intracellular lipid accumulation (Oil Red O) in 3T3-L1 cells

    decreases

    PE decreased lipid accumulation at 250 μg/mL during adipocyte differentiation

    PMID 31137922 · one of two readings recorded this

  • liver fat globule size (Oil Red O)

    decreases, p = 0.001

    the PE-M + CLA group showed the biggest reduction in fat globule size (72.5% of that in the HFD group, p < 0.001)

    PMID 31137922 · one of two readings recorded this

  • liver fat globule size (Oil Red O)

    decreases

    After treatment with FX or PE, the lipid droplet numbers decreased and the fat globule sizes reduced strongly to 75.66% of that in the HFD group in a dose-dependent manner

    PMID 31137922 · one of two readings recorded this

  • liver triglyceride level

    decreases

    In Figure 3C, the level of liver in TG in the PE-treated group reduced significantly and dose-dependently

    PMID 31137922 · one of two readings recorded this

  • liver weight

    decreases

    PE treatment groups (PE-L, PE-M, PE-H) and the PE-M plus CLA group showed significantly lower weight values (1.12%~7.45% at p < 0.001 or p < 0.01) than in the HFD group

    PMID 31137922 · one of two readings recorded this

  • PPARγ expression in adipose tissue

    decreases

    PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively

    PMID 31137922 · one of two readings recorded this

  • PPARγ expression in adipose tissue

    decreases

    PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively

    PMID 31137922 · one of two readings recorded this

  • PPARγ expression in adipose tissue

    decreases

    PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively

    PMID 31137922 · one of two readings recorded this

  • PPARγ expression in adipose tissue

    decreases

    PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively

    PMID 31137922 · one of two readings recorded this

  • PPARγ protein level in 3T3-L1 cells

    decreases

    At high levels, FX and PE clearly decreased PPARγ levels and dose-dependently increased the UCP1 level

    PMID 31137922 · one of two readings recorded this

  • serum ALT

    decreases

    FX and PE-M + CLA treatment significantly decreased ALT levels, whereas PE treatment slightly decreased ALT levels, compared with those in the HFD group

    PMID 31137922 · one of two readings recorded this

  • serum aspartate aminotransferase (AST) in HFD-fed mice

    no effect, slight decrease, difference not statistically significant

    Not recorded as a finding: paper states the AST decrease was not statistically significant, with a direction word 'slight decrease' and no estimate; not recorded as a claim

    The FX, PE, and PE-M + CLA groups showed a slight decrease in AST levels compared with the HFD group, although the difference was not statistically significant.

    PMID 31137922 · one of two readings recorded this

  • serum AST

    no effect

    The FX, PE, and PE-M + CLA groups showed a slight decrease in AST levels compared with the HFD group, although the difference was not statistically significant

    PMID 31137922 · one of two readings recorded this

  • serum LDL cholesterol, HITACHI 7180 chemistry analyser, HFD mice given FX 0.1 mg/kg/day

    no effect

    Not recorded as a finding: object span 'LDL' is not an accepted span for the LDL cholesterol node; sentence is otherwise usable

    FX treatment did not affect the levels of LDL, which is generally considered as a pathological marker.

    PMID 31137922 · one of two readings recorded this

  • serum LDL

    no effect

    FX treatment did not affect the levels of LDL, which is generally considered as a pathological marker

    PMID 31137922 · one of two readings recorded this

  • serum LDL

    decreases

    PE administration decreased the LDL levels in a dose-dependent manner, especially PE-H, which significantly decreased the LDL levels

    PMID 31137922 · one of two readings recorded this

  • serum TC and HDL

    no effect

    Neither FX nor PE affected the HFD-induced increase in TC and high-density lipoprotein (HDL) levels

    PMID 31137922 · one of two readings recorded this

  • serum TC and LDL

    increases

    the HFD group showed a slight increase in the level of triacylglyceride (TG) and a significant increase in total cholesterol (TC) and low-density lipoprotein (LDL) compare with the ND group

    PMID 31137922 · one of two readings recorded this

  • serum total cholesterol and HDL in HFD mice given FX or Phaeodactylum extract

    no effect

    Not recorded as a finding: sentence pools FX with the extract (PE) and HDL span is not an accepted span for the HDL node

    Neither FX nor PE affected the HFD-induced increase in TC and high-density lipoprotein (HDL) levels.

    PMID 31137922 · one of two readings recorded this

  • serum triacylglyceride (TG)

    decreases

    Administration of PE-M and PE-M + CLA for 6 weeks significantly decreased the TG level compared with that in the HFD group

    PMID 31137922 · one of two readings recorded this

  • subcutaneous fat volume (micro CT)

    decreases

    for subcutaneous fat, the values in the PE-treated groups were 67.68~76.78% of that of the HFD group

    PMID 31137922 · one of two readings recorded this

  • total fat volume (micro CT)

    decreases

    The total fat volumes in the PE-treated groups were 53.30~65.66% of that in the HFD group

    PMID 31137922 · one of two readings recorded this

  • UCP1 expression in adipose tissue

    increases

    UCP1 expression levels in the PE-M, PE-H, and PE-M + CLA groups were 2.02-, 2.34-, and 2.35-fold higher, respectively

    PMID 31137922 · one of two readings recorded this

  • UCP1 expression in adipose tissue

    increases

    UCP1 expression levels in the PE-M, PE-H, and PE-M + CLA groups were 2.02-, 2.34-, and 2.35-fold higher, respectively

    PMID 31137922 · one of two readings recorded this

  • UCP1 expression in adipose tissue

    increases

    UCP1 expression levels in the PE-M, PE-H, and PE-M + CLA groups were 2.02-, 2.34-, and 2.35-fold higher, respectively

    PMID 31137922 · one of two readings recorded this

  • UCP1 protein level in 3T3-L1 cells

    increases

    At high levels, FX and PE clearly decreased PPARγ levels and dose-dependently increased the UCP1 level

    PMID 31137922 · one of two readings recorded this

  • acetylated FoxO3α

    decreases

    Fx and Rsv decreased the acetylated FoxO3α induced by HG, respectively

    PMID 31842414 · one of two readings recorded this

  • fibronectin and collagen IV expression, ROS by DCFH-DA, mitochondrial membrane potential in high-glucose rat glomerular mesangial cells

    decreases, Fx reduced FN and collagen IV expression induced by HG

    Not recorded as a finding: no outcome node for in vitro extracellular matrix protein expression or cellular ROS

    Here, we found that Fx can effectively reduce the expression of FN and collagen IV induced by HG in GMCs, suggesting that Fx can alleviate the accumulation of ECM in DN.

    PMID 31842414 · both readings recorded this

  • fibronectin (FN) and collagen IV expression

    decreases

    we found that Fx can effectively reduce the expression of FN and collagen IV induced by HG in GMCs

    PMID 31842414 · one of two readings recorded this

  • FoxO3α expression after Sirt1 inhibitor EX527 or Akt activator SC79

    no effect

    Fx restored the expression of FoxO3α inhibited by HG but could not restore the expression of FoxO3α in GMCs pretreated with EX527 and SC79, respectively

    PMID 31842414 · one of two readings recorded this

  • FoxO3α expression and phosphorylated FoxO3α (S253) with HG over time

    decreases

    The results showed that the expression of FoxO3α was the lowest at 12 h of HG treatment, while phosphorylated FoxO3α (S253) was the highest at this time point

    PMID 31842414 · one of two readings recorded this

  • FoxO3α expression and phosphorylated FoxO3α

    increases

    It is gratifying to see that Fx can successfully reverse the decrease expression of FoxO3α and the increase of phosphorylated FoxO3α induced by HG

    PMID 31842414 · one of two readings recorded this

  • mitochondrial membrane potential

    increases

    The results showed that the membrane potential decreased significantly in the HG group, which was counteracted by Fx

    PMID 31842414 · one of two readings recorded this

  • MnSOD expression

    increases

    Fx was more effective than both in promoting the expression of MnSOD in the HG condition

    PMID 31842414 · one of two readings recorded this

  • nuclear FoxO3α after Akt activator SC79

    decreases

    Akt inhibitor MK2206 significantly increased the FoxO3α in the nucleus, while Akt activator SC79 abolished concentration of FoxO3α in the nucleus induced by Fx

    PMID 31842414 · one of two readings recorded this

  • nuclear FoxO3α after Sirt1 inhibitor EX527

    decreases

    the addition of Sirt1 inhibitor EX527 abolished Fx-induced FoxO3α nuclear transportation

    PMID 31842414 · one of two readings recorded this

  • nuclear FoxO3α

    increases

    The results showed that HG treatment decreased the FoxO3α in the nucleus; however, increased FoxO3α was observed in the nucleus after Fx treatment

    PMID 31842414 · one of two readings recorded this

  • p-Akt activation

    decreases

    Fx and MK2206, a specific inhibitor of Akt, successfully reversed the activation of Akt induced by HG

    PMID 31842414 · one of two readings recorded this

  • ROS production

    decreases

    Fx effectively inhibited the overproduction of ROS induced by HG in an Akt/Sirt1/FoxO3α-dependent manner

    PMID 31842414 · one of two readings recorded this

  • Sirt1 protein level

    increases

    The Sirt1 activator Rsv effectively promoted the protein level of Sirt1 under HG, and Fx produced similar pharmacological effects to Rsv

    PMID 31842414 · one of two readings recorded this

  • AD pathology improvement

    decreases

    0.1% FX significantly improved AD pathology with better reproducibility than 0.1% TAC

    PMID 32235696 · one of two readings recorded this

  • BMMC degranulation

    decreases

    After differentiation for three weeks, FX showed concentration-dependent inhibitory effects on degranulation of BMMCs (Figure S1C)

    PMID 32235696 · one of two readings recorded this

  • eosinophil infiltration

    decreases

    eosinophils with deeply stained granules were often found only in Vas treated skin

    PMID 32235696 · one of two readings recorded this

  • epidermal thickening

    no effect

    Pathological analysis revealed no epidermal thickening after five weeks of continuous application of each compound

    PMID 32235696 · one of two readings recorded this

  • FcεRIα expression

    decreases

    FX or TAC significantly inhibited FcεRlα

    PMID 32235696 · one of two readings recorded this

  • GATA1 and GATA2 expression

    modulates

    qRT-PCR analysis showed that GATA1 and GATA2 were regulated by FX or TAC in vivo

    PMID 32235696 · one of two readings recorded this

  • Il-10+TGF-β+Sca1+ ILCreg in dermis

    increases

    Il-10+TGF-β+Sca1+ ILCreg were dominantly observed in FX treated groups in dermis compared to Vas or TAC treated groups

    PMID 32235696 · one of two readings recorded this

  • Il-17 expression

    decreases

    Il-17 expression levels were significantly suppressed by TAC

    PMID 32235696 · one of two readings recorded this

  • Il-2 and Il-10 expression

    increases

    FX but not TAC dramatically stimulated Il-2 and Il-10 expression levels in Nc/Nga mice

    PMID 32235696 · one of two readings recorded this

  • Il-33 expression

    decreases

    Il-33 expression levels were downregulated in FX or TAC treated skin to a similar extent

    PMID 32235696 · one of two readings recorded this

  • Il-5 and Il-13 expression

    increases

    FX significantly enhanced the expression of Il-5 and Il-13

    PMID 32235696 · one of two readings recorded this

  • inflammatory cytokine expression, NF-κB activity and viability in HaCaT cells

    no effect

    FX or TAC did not influence inflammatory cytokine expression levels (Figure S2A,B), NF-κB activities (Figure S2C), or cell viabilities in human keratinocytes HaCaT cells (Figure S3)

    PMID 32235696 · one of two readings recorded this

  • lymphocyte proliferation

    no effect

    There was no effect on lymphocytes proliferation (Figure S1B)

    PMID 32235696 · one of two readings recorded this

  • modified clinical skin severity score (itch, erythema/hemorrhage, edema, excoriation/erosion, scaling/dryness, each graded 0-3) and scratching behaviour in NC/Nga mice given 0.1% fucoxanthin in Vaseline topically, versus Vaseline and 0.1% tacrolimus; serum IgE; mast cell and eosinophil counts; skin cytokine expression by qRT-PCR

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    FX significantly reduced the modified clinical skin severity score from day 22 after the start of application.

    PMID 32235696 · one of two readings recorded this

  • modified clinical skin severity score

    decreases

    FX significantly reduced the modified clinical skin severity score from day 22 after the start of application

    PMID 32235696 · one of two readings recorded this

  • scratching behavior (itch) and modified clinical skin severity score in NC/Nga mice with atopic dermatitis, topical 0.1% FX vs Vaseline vs 0.1% tacrolimus

    decreases, FX significantly reduced the modified clinical skin severity score from day 22

    Not recorded as a finding: this platform holds no node for the endpoint

    FX significantly reduced the modified clinical skin severity score from day 22 after the start of application.

    PMID 32235696 · one of two readings recorded this

  • scratching behavior (itch)

    decreases

    Until day 15, the scratching behavior was reduced by FX or TAC, but increased again on day 35

    PMID 32235696 · one of two readings recorded this

  • scratching behavior (itch)

    increases

    Until day 15, the scratching behavior was reduced by FX or TAC, but increased again on day 35

    PMID 32235696 · one of two readings recorded this

  • scratching behavior (itch)

    decreases

    Although the improvement effect was also recognized by TAC ointment, the improvement effect of FX was significant

    PMID 32235696 · one of two readings recorded this

  • serum IgE

    no effect

    elevated serum IgE values in Vas-, FX-, or TAC-treated mice were not changed, respectively

    PMID 32235696 · one of two readings recorded this

  • TGF-β expression

    increases

    TGF-β expression levels were dramatically upregulated by each compound

    PMID 32235696 · one of two readings recorded this

  • toluidine blue-positive mast cell number

    decreases

    the number of toluidine blue (TB)-positive mast cells was significantly reduced as compared with the Vas treated group

    PMID 32235696 · one of two readings recorded this

  • trans-epidermal water loss (TEWL)

    unclear

    From the follow-up analysis of trans-epidermal water loss (TEWL) values over time, transcutaneous water evaporation above 40 g/m2·hour was recorded in all mice

    PMID 32235696 · one of two readings recorded this

  • TSLP expression

    no effect

    Thymic stromal lymphopoietin (TSLP) expression levels were not influenced by FX or TAC, while TSLP receptor (TSLPR) expression levels were downregulated by FX or TAC to a similar extent

    PMID 32235696 · one of two readings recorded this

  • TSLP receptor (TSLPR) expression

    decreases

    Thymic stromal lymphopoietin (TSLP) expression levels were not influenced by FX or TAC, while TSLP receptor (TSLPR) expression levels were downregulated by FX or TAC to a similar extent

    PMID 32235696 · one of two readings recorded this

  • Expression of MMP-1, MMP-2 and MMP-9

    decreases

    it significantly decreased the expression of matrix metalloproteinase (MMP)-1, MMP-2, and MMP-9 at 25 µg/ml

    PMID 32271708 · one of two readings recorded this

  • Fibroblast proliferation

    no effect

    The concentrate (up to 25 µg/ml) did not affect the proliferation of human fibroblasts

    PMID 32271708 · one of two readings recorded this

  • Procollagen synthesis

    increases

    the concentrate significantly increased procollagen synthesis in the fibroblasts at 12.5 and 25 µg/ml

    PMID 32271708 · one of two readings recorded this

  • Skin moisture and elasticity

    increases

    skin moisture and elasticity increased significantly from week 4

    PMID 32271708 · one of two readings recorded this

  • Wrinkles around the eyes

    decreases

    Evaluation of wrinkles around the eyes using the replica method showed a statistically significant decrease in wrinkles at week 8

    PMID 32271708 · one of two readings recorded this

  • bioaccessibility and physicochemical stability of fucoxanthin achieved via nano/micro-encapsulation delivery systems for oral food/nutraceutical use, no clinical or physiological outcome measured

    increases, these formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin, no quantitative figure given

    Not recorded as a finding: this platform holds no node for the endpoint

    These formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin.

    PMID 33151231 · one of two readings recorded this

  • bioaccessibility and physicochemical stability of fucoxanthin after encapsulation

    increases

    These formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin.

    PMID 33151231 · one of two readings recorded this

  • bioaccessibility and stability of fucoxanthin encapsulated in nano/micro-delivery systems

    increases

    These formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin.

    PMID 33151231 · one of two readings recorded this

  • BALF protein concentration

    decreases

    the protein concentration of BALF was significantly increased after LPS stimulation, whereas the pre-treatment of Fucoxanthin could reverse this increase

    PMID 33323555 · one of two readings recorded this

  • BALF total protein concentration by BCA assay, BALF cell number, and lung wet/dry weight ratio in LPS-induced acute lung injury in mice; COX-2 and iNOS expression in RAW264.7 cells

    decreases, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio

    Not recorded as a finding: this platform holds no node for the endpoint

    Nevertheless, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio.

    PMID 33323555 · one of two readings recorded this

  • cell number in BALF

    decreases

    The LPS stimulation led to a significant increase in the number of cells in the BALF, which was decreased by pre-treatment with Fucoxanthin

    PMID 33323555 · one of two readings recorded this

  • COX-2 and iNOS expression in lung tissue

    decreases

    Fucoxanthin significantly attenuated LPS-induced lung inflammation, as evidenced by COX-2 and iNOS expression in lung tissue

    PMID 33323555 · one of two readings recorded this

  • COX-2 and iNOS protein expression in LPS-stimulated RAW264.7 cells

    decreases

    Western blot analysis also showed that Fucoxanthin could dramatically reduce the protein expression of COX-2 and iNOS induced by LPS

    PMID 33323555 · one of two readings recorded this

  • lung histopathology (alveolar wall thickness, hemorrhage, collapse, infiltration)

    decreases

    As a comparison, the group pretreated with Fucoxanthin displayed very little histopathological changes

    PMID 33323555 · one of two readings recorded this

  • lung macrophage infiltration (CD68)

    decreases

    Pre-treatment with Fucoxanthin significantly attenuated LPS-induced lung macrophage infiltration into the lung

    PMID 33323555 · one of two readings recorded this

  • lung wet/dry weight ratio, BALF total protein (BCA) and BALF cell count in LPS-induced acute lung injury in mice given fucoxanthin 10 mg/kg i.v.; COX-2, iNOS, IL-6, TNF-α expression in LPS-stimulated RAW264.7 cells

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Nevertheless, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio.

    PMID 33323555 · one of two readings recorded this

  • lung wet/dry weight ratio

    decreases

    Nevertheless, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio

    PMID 33323555 · one of two readings recorded this

  • mRNA expression of COX-2, iNOS, IL-10, IL-6, TNF-α, IL-1β in LPS-stimulated RAW264.7 cells

    decreases

    pre-treatment with Fucoxanthin completely diminished the stimulatory effects of LPS in a dose-dependent manner

    PMID 33323555 · one of two readings recorded this

  • NLRP3 signal pathway

    no effect

    The results showed that Fucoxanthin did not affect the NLRP3 signal pathway

    PMID 33323555 · one of two readings recorded this

  • nuclear translocation of NF-κB

    decreases

    As shown in Figure 4A, Fucoxanthin effectively blocked the nuclear translocation of NF-κB

    PMID 33323555 · one of two readings recorded this

  • p-NF-κB (p-p65) expression

    decreases

    The results showed that Fucoxanthin only affected the expression level of p-NF-κB (p-p65), but not the expression level of total NF-κB (p65)

    PMID 33323555 · one of two readings recorded this

  • RAW264.7 cell viability (CCK-8)

    no effect

    As shown in Figure 1B, RAW264.7 cells were treated with 0-20 μM Fucoxanthin for 24 hours had no cytotoxic effect, whereas cell viability was significantly reduced at the concentration of 40 μM

    PMID 33323555 · one of two readings recorded this

  • RAW264.7 cell viability (CCK-8)

    decreases

    As shown in Figure 1B, RAW264.7 cells were treated with 0-20 μM Fucoxanthin for 24 hours had no cytotoxic effect, whereas cell viability was significantly reduced at the concentration of 40 μM

    PMID 33323555 · one of two readings recorded this

  • TLR4/MyD88 signaling in LPS-stimulated RAW264.7 cells

    decreases

    As we expected, Fucoxanthin effectively suppressed the TLR4/MyD88 signaling pathway

    PMID 33323555 · one of two readings recorded this

  • total NF-κB (p65) expression

    no effect

    The results showed that Fucoxanthin only affected the expression level of p-NF-κB (p-p65), but not the expression level of total NF-κB (p65)

    PMID 33323555 · one of two readings recorded this

  • cytosolic Nrf2 expression

    decreases

    Expression of nuclear Nrf2 significantly increased, while cytosolic Nrf2 expression dose-dependently decreased

    PMID 33673704 · one of two readings recorded this

  • DC-STAMP mRNA expression

    decreases

    DC-STAMP mRNA expression was significantly decreased upon treatment with FX in a dose-dependent manner

    PMID 33673704 · one of two readings recorded this

  • ERK and p38 phosphorylation

    decreases

    The treatment of RAW264.7 cells with FX significantly reduced the phosphorylation of ERK and p38 in a concentration-dependent manner

    PMID 33673704 · one of two readings recorded this

  • JNK, NF-κB and PI3K phosphorylation

    no effect

    However, JNK, NF-κB, and PI3K phosphorylation was not altered following FX treatment

    PMID 33673704 · one of two readings recorded this

  • MMP-9 level in culture supernatant

    decreases

    cells treated with 5 μM FX showed a significant decrease in MMP-9 levels

    PMID 33673704 · one of two readings recorded this

  • NFATc1 expression

    decreases

    The expression of NFATc1 in sRANKL- or TNF/IL-6-stimulated RAW264.7 cells decreased upon treatment with FX in a dose-dependent manner

    PMID 33673704 · one of two readings recorded this

  • nuclear Nrf2 expression

    increases

    Expression of nuclear Nrf2 significantly increased, while cytosolic Nrf2 expression dose-dependently decreased

    PMID 33673704 · one of two readings recorded this

  • osteoclast differentiation of human CD14+ monocytes

    decreases

    In experiments using human CD14+ monocytes, 0 to 5 μM of FX dose-dependently suppressed RANKL- and TNF-α/IL-6-induced osteoclast differentiation from osteoclast precursors

    PMID 33673704 · one of two readings recorded this

  • procaspase-3 and PARP cleavage

    no effect

    no cleavage of procaspase-3 and poly ADP ribose polymerase (PARP; Figure 1B) was detected in cells treated with ≤10 μM FX

    PMID 33673704 · one of two readings recorded this

  • proportion of phospho-Nrf2 in nucleus versus cytoplasm

    increases

    The proportions of phospho-Nrf2 expression in the nucleus compared to in the cytoplasm were significantly augmented by FX

    PMID 33673704 · one of two readings recorded this

  • RAW264.7 cell viability

    decreases

    However, the number of viable cells after treatment with 10 μM of FX was significantly lower than the number of untreated cells was

    PMID 33673704 · one of two readings recorded this

  • RAW264.7 cell viability

    no effect

    FX did not affect cell viability at a concentration of ≤5 μM

    PMID 33673704 · one of two readings recorded this

  • resorption pit area

    decreases

    the resorption pit area was significantly decreased upon treatment with FX in a dose-dependent manner

    PMID 33673704 · one of two readings recorded this

  • total Nrf2 level in cell lysates

    no effect

    Nrf2 levels in total cell lysates were not affected by FX treatment

    PMID 33673704 · one of two readings recorded this

  • TRAP-positive multinucleated cells (RAW264.7)

    decreases

    Under these conditions, FX treatment decreased the number of TRAP-positive multinucleated cells in a dose-dependent manner

    PMID 33673704 · one of two readings recorded this

  • TRAP-positive multinucleated osteoclast count and resorption pit area in RAW264.7 cells; MMP-9 by ELISA

    decreases, dose-dependent decrease

    Not recorded as a finding: no outcome node for osteoclast differentiation or resorption pit area in cell culture

    As shown in Figure 3, the resorption pit area was significantly decreased upon treatment with FX in a dose-dependent manner.

    PMID 33673704 · one of two readings recorded this

  • ARE-luciferase activity with FUC pretreatment

    increases, p = 0.05

    FUC pretreatment significantly increased the activity of ARE-luciferase in 6-OHDA-induced PC12 cells compared with the 6-OHDA treatment group (P < 0.05)

    PMID 33777321 · one of two readings recorded this

The whole record — 601 rows